Emerging trends in hepatocellular carcinoma incidence and mortality

Basile Njei, Yaron Rotman, Ivo Ditah, Joseph K. Lim – 20 August 2014 – The rise in incidence of hepatocellular carcinoma (HCC) in the United States has been well documented. The purpose of this analysis was to examine temporal trends in HCC incidence, mortality, and survival within the U.S. population. The Surveillance, Epidemiology, and End Results data were used to examine incidence and incidence‐based (IB) mortality in HCC from 1973 to 2011. Secular trends in age‐adjusted incidence and IB mortality by sex and cancer stage were characterized using the Joinpoint Regression program.

Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test

Beom Kyung Kim, Hyon‐Suk Kim, Eun Jin Yoo, Eun Ji Oh, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Seung Up Kim, Young Nyun Park – 20 August 2014 – Serum fibrosis markers, such as the enhanced liver fibrosis (ELF) test, have been suggested as alternatives for liver biopsy (LB) in assessing liver fibrosis. We investigated the efficacy of the ELF test in predicting development of liver‐related events (LREs) in patients with chronic hepatitis B (CHB). A total of 170 patients (103 men; 60.6%) with CHB who underwent LB and serological tests for determining ELFs were enrolled.

Emerging trends in hepatocellular carcinoma incidence and mortality

Basile Njei, Yaron Rotman, Ivo Ditah, Joseph K. Lim – 20 August 2014 – The rise in incidence of hepatocellular carcinoma (HCC) in the United States has been well documented. The purpose of this analysis was to examine temporal trends in HCC incidence, mortality, and survival within the U.S. population. The Surveillance, Epidemiology, and End Results data were used to examine incidence and incidence‐based (IB) mortality in HCC from 1973 to 2011. Secular trends in age‐adjusted incidence and IB mortality by sex and cancer stage were characterized using the Joinpoint Regression program.

Targeting mitochondria with methylene blue protects mice against acetaminophen‐induced liver injury

Kang Kwang Lee, Naoki Imaizumi, Sally R. Chamberland, Nathan N. Alder, Urs A. Boelsterli – 20 August 2014 – Acetaminophen (APAP) overdose is a frequent cause of drug‐induced liver injury and the most frequent cause of acute liver failure in the Western world. Previous studies with mouse models have revealed that impairment of mitochondrial respiration is an early event in the pathogenesis, but the exact mechanisms have remained unclear, and therapeutic approaches to specifically target mitochondria have been insufficiently explored.

Liver sinusoidal endothelial cells in hepatic fibrosis

Laurie D. DeLeve – 18 August 2014 – Capillarization, lack of liver sinusoidal endothelial cell (LSEC) fenestration, and formation of an organized basement membrane not only precedes fibrosis, but is also permissive for hepatic stellate cell activation and fibrosis. Thus, dysregulation of the LSEC phenotype is a critical step in the fibrotic process. Both a vascular endothelial growth factor (VEGF)‐stimulated, nitric oxide (NO)‐independent pathway and a VEGF‐stimulated NO‐dependent pathway are necessary to maintain the differentiated LSEC phenotype.

Tissue inhibitor of metalloproteinases (TIMP)‐1 creates a premetastatic niche in the liver through SDF‐1/CXCR4‐dependent neutrophil recruitment in mice

Bastian Seubert, Barbara Grünwald, Julia Kobuch, Haissi Cui, Florian Schelter, Susanne Schaten, Jens T. Siveke, Ngee H. Lim, Hideaki Nagase, Nicole Simonavicius, Mathias Heikenwalder, Thomas Reinheckel, Jonathan P. Sleeman, Klaus‐Peter Janssen, Percy A. Knolle, Achim Krüger – 18 August 2014 – Due to its ability to inhibit prometastatic matrix metalloproteinases, tissue inhibitor of metalloproteinases (TIMP)‐1 has been thought to suppress tumor metastasis.

Subscribe to